Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.
Identifieur interne : 000100 ( PubMed/Curation ); précédent : 000099; suivant : 000101Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.
Auteurs : Laurel M. Schunselaar [Pays-Bas] ; Kim Monkhorst [Pays-Bas] ; Vincent Van Der Noort [Pays-Bas] ; Ruud Wijdeven [Pays-Bas] ; Dennis Peters [Pays-Bas] ; Wilbert Zwart [Pays-Bas] ; Jacques Neefjes [Pays-Bas] ; Paul Baas [Pays-Bas]Source :
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [ 1556-1380 ] ; 2018.
Descripteurs français
- KwdFr :
- Analyse de survie, Anticorps monoclonaux (métabolisme), Glycoprotéines (métabolisme), Humains, Mésothéliome (anatomopathologie), Mésothéliome (mortalité), Mésothéliome (traitement médicamenteux), Résultat thérapeutique, Trophoblastes (métabolisme), Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (mortalité), Tumeurs du poumon (traitement médicamenteux).
- MESH :
- anatomopathologie : Mésothéliome, Tumeurs du poumon.
- mortalité : Mésothéliome, Tumeurs du poumon.
- métabolisme : Anticorps monoclonaux, Glycoprotéines, Trophoblastes.
- traitement médicamenteux : Mésothéliome, Tumeurs du poumon.
- Analyse de survie, Humains, Résultat thérapeutique.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (metabolism), Glycoproteins (metabolism), Humans, Lung Neoplasms (drug therapy), Lung Neoplasms (mortality), Lung Neoplasms (pathology), Mesothelioma (drug therapy), Mesothelioma (mortality), Mesothelioma (pathology), Progression-Free Survival, Survival Analysis, Treatment Outcome, Trophoblasts (metabolism).
- MESH :
- chemical , metabolism : Antibodies, Monoclonal, Glycoproteins.
- drug therapy : Lung Neoplasms, Mesothelioma.
- metabolism : Trophoblasts.
- mortality : Lung Neoplasms, Mesothelioma.
- pathology : Lung Neoplasms, Mesothelioma.
- Humans, Progression-Free Survival, Survival Analysis, Treatment Outcome.
Abstract
The prognosis for patients with mesothelioma is poor, which prompts the need for the development of better treatment options. Antibody drug conjugates (ADCs) are gaining interest as a therapeutic strategy in mesothelioma. Trophoblast glycoprotein (5T4) is an oncofetal protein overexpressed in mesothelioma with low expression in normal tissue and therefore a good candidate for ADC treatment. Here, we evaluated and manipulated 5T4 as a suitable antigen for ADC targeted therapy in patients with mesothelioma.
DOI: 10.1016/j.jtho.2018.06.008
PubMed: 29959059
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000100
Links to Exploration step
pubmed:29959059Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.</title><author><name sortKey="Schunselaar, Laurel M" sort="Schunselaar, Laurel M" uniqKey="Schunselaar L" first="Laurel M" last="Schunselaar">Laurel M. Schunselaar</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Monkhorst, Kim" sort="Monkhorst, Kim" uniqKey="Monkhorst K" first="Kim" last="Monkhorst">Kim Monkhorst</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Pathology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Van Der Noort, Vincent" sort="Van Der Noort, Vincent" uniqKey="Van Der Noort V" first="Vincent" last="Van Der Noort">Vincent Van Der Noort</name><affiliation wicri:level="1"><nlm:affiliation>Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Biometrics Department, Netherlands Cancer Institute, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Wijdeven, Ruud" sort="Wijdeven, Ruud" uniqKey="Wijdeven R" first="Ruud" last="Wijdeven">Ruud Wijdeven</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden</wicri:regionArea></affiliation></author><author><name sortKey="Peters, Dennis" sort="Peters, Dennis" uniqKey="Peters D" first="Dennis" last="Peters">Dennis Peters</name><affiliation wicri:level="1"><nlm:affiliation>Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Zwart, Wilbert" sort="Zwart, Wilbert" uniqKey="Zwart W" first="Wilbert" last="Zwart">Wilbert Zwart</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Neefjes, Jacques" sort="Neefjes, Jacques" uniqKey="Neefjes J" first="Jacques" last="Neefjes">Jacques Neefjes</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden</wicri:regionArea></affiliation></author><author><name sortKey="Baas, Paul" sort="Baas, Paul" uniqKey="Baas P" first="Paul" last="Baas">Paul Baas</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: p.baas@nki.nl.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29959059</idno><idno type="pmid">29959059</idno><idno type="doi">10.1016/j.jtho.2018.06.008</idno><idno type="wicri:Area/PubMed/Corpus">000100</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000100</idno><idno type="wicri:Area/PubMed/Curation">000100</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000100</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.</title><author><name sortKey="Schunselaar, Laurel M" sort="Schunselaar, Laurel M" uniqKey="Schunselaar L" first="Laurel M" last="Schunselaar">Laurel M. Schunselaar</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Monkhorst, Kim" sort="Monkhorst, Kim" uniqKey="Monkhorst K" first="Kim" last="Monkhorst">Kim Monkhorst</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Pathology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Van Der Noort, Vincent" sort="Van Der Noort, Vincent" uniqKey="Van Der Noort V" first="Vincent" last="Van Der Noort">Vincent Van Der Noort</name><affiliation wicri:level="1"><nlm:affiliation>Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Biometrics Department, Netherlands Cancer Institute, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Wijdeven, Ruud" sort="Wijdeven, Ruud" uniqKey="Wijdeven R" first="Ruud" last="Wijdeven">Ruud Wijdeven</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden</wicri:regionArea></affiliation></author><author><name sortKey="Peters, Dennis" sort="Peters, Dennis" uniqKey="Peters D" first="Dennis" last="Peters">Dennis Peters</name><affiliation wicri:level="1"><nlm:affiliation>Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Zwart, Wilbert" sort="Zwart, Wilbert" uniqKey="Zwart W" first="Wilbert" last="Zwart">Wilbert Zwart</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Neefjes, Jacques" sort="Neefjes, Jacques" uniqKey="Neefjes J" first="Jacques" last="Neefjes">Jacques Neefjes</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden</wicri:regionArea></affiliation></author><author><name sortKey="Baas, Paul" sort="Baas, Paul" uniqKey="Baas P" first="Paul" last="Baas">Paul Baas</name><affiliation wicri:level="1"><nlm:affiliation>Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: p.baas@nki.nl.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea></affiliation></author></analytic><series><title level="j">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</title><idno type="eISSN">1556-1380</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (metabolism)</term><term>Glycoproteins (metabolism)</term><term>Humans</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (mortality)</term><term>Lung Neoplasms (pathology)</term><term>Mesothelioma (drug therapy)</term><term>Mesothelioma (mortality)</term><term>Mesothelioma (pathology)</term><term>Progression-Free Survival</term><term>Survival Analysis</term><term>Treatment Outcome</term><term>Trophoblasts (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de survie</term><term>Anticorps monoclonaux (métabolisme)</term><term>Glycoprotéines (métabolisme)</term><term>Humains</term><term>Mésothéliome (anatomopathologie)</term><term>Mésothéliome (mortalité)</term><term>Mésothéliome (traitement médicamenteux)</term><term>Résultat thérapeutique</term><term>Trophoblastes (métabolisme)</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (mortalité)</term><term>Tumeurs du poumon (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Glycoproteins</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mésothéliome</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Neoplasms</term><term>Mesothelioma</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Trophoblasts</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Lung Neoplasms</term><term>Mesothelioma</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Mésothéliome</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Glycoprotéines</term><term>Trophoblastes</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung Neoplasms</term><term>Mesothelioma</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mésothéliome</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Progression-Free Survival</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term><term>Humains</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The prognosis for patients with mesothelioma is poor, which prompts the need for the development of better treatment options. Antibody drug conjugates (ADCs) are gaining interest as a therapeutic strategy in mesothelioma. Trophoblast glycoprotein (5T4) is an oncofetal protein overexpressed in mesothelioma with low expression in normal tissue and therefore a good candidate for ADC treatment. Here, we evaluated and manipulated 5T4 as a suitable antigen for ADC targeted therapy in patients with mesothelioma.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29959059</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-1380</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2018</Year><Month>10</Month></PubDate></JournalIssue><Title>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</Title><ISOAbbreviation>J Thorac Oncol</ISOAbbreviation></Journal><ArticleTitle>Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.</ArticleTitle><Pagination><MedlinePgn>1577-1587</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1556-0864(18)30717-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtho.2018.06.008</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The prognosis for patients with mesothelioma is poor, which prompts the need for the development of better treatment options. Antibody drug conjugates (ADCs) are gaining interest as a therapeutic strategy in mesothelioma. Trophoblast glycoprotein (5T4) is an oncofetal protein overexpressed in mesothelioma with low expression in normal tissue and therefore a good candidate for ADC treatment. Here, we evaluated and manipulated 5T4 as a suitable antigen for ADC targeted therapy in patients with mesothelioma.</AbstractText><AbstractText Label="METHODS">Expression of the 5T4 antigen is evaluated in (primary) mesothelioma cell lines and biopsy specimens, and correlated with clinical outcome. Internalization was assessed in 5T4 expressing cells. The cytotoxicity of three different 5T4-targeting ADCs was tested on (primary) mesothelioma cells.</AbstractText><AbstractText Label="RESULTS">5T4 was expressed in 10 of 12 (primary) cell lines. Most biopsy specimens stained positive for the 5T4 antigen, with marked differences in staining intensity and percentage of positive cells. High expression correlated with long progression-free survival. Both free antibody and ADCs targeting 5T4 were internalized and entered lysosomal compartments. Cytotoxicity experiments showed that cell lines with a high expression for 5T4 were sensitive to two of three ADCs. Lack of efficacy for the third ADC could be restored by neutralizing lysosomal compartments with chloroquine.</AbstractText><AbstractText Label="CONCLUSIONS">The 5T4 antigen is expressed in mesothelioma and 5T4-based ADCs are internalized in lysosomes. Two of three ADCs were capable of killing the mesothelioma cells; the third ADC required additional lysosomal neutralization for its effect. 5T4-based ADCs would be a selective strategy for the treatment of mesothelioma.</AbstractText><CopyrightInformation>Copyright © 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schunselaar</LastName><ForeName>Laurel M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monkhorst</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Noort</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijdeven</LastName><ForeName>Ruud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwart</LastName><ForeName>Wilbert</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neefjes</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell and Chemical Biology, Oncode Institute within Leiden University Medical Center, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baas</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: p.baas@nki.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Thorac Oncol</MedlineTA><NlmUniqueID>101274235</NlmUniqueID><ISSNLinking>1556-0864</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C562839">Mesothelioma, Malignant</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008654" MajorTopicYN="N">Mesothelioma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014327" MajorTopicYN="N">Trophoblasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">5T4</Keyword><Keyword MajorTopicYN="Y">Antibody-drug conjugate</Keyword><Keyword MajorTopicYN="Y">Lysosome</Keyword><Keyword MajorTopicYN="Y">Malignant pleural mesothelioma</Keyword><Keyword MajorTopicYN="Y">treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>02</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29959059</ArticleId><ArticleId IdType="pii">S1556-0864(18)30717-2</ArticleId><ArticleId IdType="doi">10.1016/j.jtho.2018.06.008</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000100 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000100 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:29959059
|texte= Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:29959059" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |